(Q55071600)

17 June 2018

title

HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy. (English)

1 reference

17 June 2018

1 reference

16

Kyoung-Mee Kim

1 reference

17 June 2018

author name string

Sang Yun Ha

1

1 reference

17 June 2018

Jeeyun Lee

2

1 reference

17 June 2018

Jiryeon Jang

3

1 reference

17 June 2018

Jung Yong Hong

4

1 reference

17 June 2018

In-Gu Do

5

1 reference

17 June 2018

Se Hoon Park

6

1 reference

17 June 2018

Joon Oh Park

7

1 reference

17 June 2018

Min-Gew Choi

8

1 reference

17 June 2018

Tae Sung Sohn

9

1 reference

17 June 2018

Jae Moon Bae

10

1 reference

17 June 2018

Sung Kim

11

1 reference

17 June 2018

Minji Kim

12

1 reference

17 June 2018

Seonwoo Kim

13

1 reference

17 June 2018

Cheol Keun Park

14

1 reference

17 June 2018

Won Ki Kang

15

1 reference

17 June 2018

language of work or name

English

0 references

publication date

4 September 2014

1 reference

17 June 2018

International Journal of Cancer

published in

1 reference

17 June 2018

volume

136

1 reference

17 June 2018

issue

7

1 reference

17 June 2018

page(s)

1629-1635

1 reference

17 June 2018

Hallmarks of Cancer: The Next Generation

cites work

1 reference

Receptor tyrosine kinase coactivation networks in cancer

21 January 2018

1 reference

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

21 January 2018

1 reference

Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells

21 January 2018

1 reference

Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.

21 January 2018

1 reference

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

21 January 2018

1 reference

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells

21 January 2018

1 reference

Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.

21 January 2018

1 reference

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

21 January 2018

1 reference

HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells

21 January 2018

1 reference

Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition.

21 January 2018

1 reference

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib

21 January 2018

1 reference

Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas

21 January 2018

1 reference

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

21 January 2018

1 reference

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

21 January 2018

1 reference

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

21 January 2018

1 reference

Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas.

21 January 2018

1 reference

MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome

21 January 2018

1 reference

EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number

21 January 2018

1 reference

MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas

21 January 2018

1 reference

A large cohort of consecutive patients confirmed frequent HER2 positivity in gastric carcinomas with advanced stages.

21 January 2018

1 reference

Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells.

21 January 2018

1 reference

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells

21 January 2018

1 reference

HER2 testing in gastric cancer: a practical approach

21 January 2018

1 reference

A novel proteomics-based clinical diagnostics technology identifies heterogeneity in activated signaling pathways in gastric cancers

21 January 2018

1 reference

A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.29159

1 reference

17 June 2018

1 reference

17 June 2018